Search clinical trials for: Tislelizumab plus Bevacizumab

Total 7599 results

Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate
Wuhan Union Hospital, China

Recruiting

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Breast Cancer | Neoadjuvant Therapy

China
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
Second Affiliated Hospital of Nanchang University

Recruiting

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Immunotherapy | Tislelizumab | Pulmonary Pleomorphic Carcinoma

China
Akeso

Recruiting

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non Small Cell Lung Cancer

China
First Affiliated Hospital Xi'an Jiaotong University

Active, not recruiting

Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES) (TINES)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Left-sided Colorectal Cancer Complicating Acute Obstruction
Peking University Cancer Hospital & Institute

Not yet recruiting

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer (PKUCH-R09)

Rectal Cancer

China
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Fudan University

Recruiting

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Metastatic Colorectal Cancer

China
University Hospital, Ghent

Completed

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

Colorectal Neoplasms

Belgium
BeiGene

Recruiting

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

China, United States, Australia, Puerto Rico
Zhejiang Cancer Hospital

Recruiting

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Immix Biopharma, Inc.
Novartis; BeiGene

Recruiting

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)

Advanced Solid Tumor

Brazil
Daping Hospital and the Research Institute of Surgery...

Recruiting

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Gastric Cancer | Rectal Cancer | Chemotherapy Effect | Radiotherapy | Immunotherapy

China
Huihua Xiong

Recruiting

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study (UTILIZABLE)

TNBC - Triple-Negative Breast Cancer

China
BriaCell Therapeutics Corporation

Recruiting

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Breast Cancer | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the Breast | Tumors, Breast

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
RenJi Hospital
BeiGene; Huidu Shanghai Medical Sciences Ltd

Recruiting

Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (TACBIN-01)

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Antineoplastic Agents | Tislelizumab Antineoplastic Agents, Immunological

China
Sun Yat-sen University

Recruiting

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Hodgkin Lymphoma | Chemotherapy Effect

China
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

Colon Cancer
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
Hebei Medical University

Unknown

Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis

Gastric Cancer | Liver Metastasis

China
Tianjin Medical University Second Hospital

Recruiting

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Not yet recruiting

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

Head and Neck Cancer | Radiation | PD-1
CHA University
Boryung Pharmaceutical Co., Ltd

Recruiting

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab (HCC)

Advanced Hepatocellular Carcinoma

Korea, Republic of
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

Resectable Hepatocellular Carcinoma
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Yanhong Deng

Recruiting

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (TRIBE-C)

Colorectal Cancer

China
Yale University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer

Melanoma | Non-small Cell Lung Cancer | Brain Metastasis

United States
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Anhui Provincial Hospital
Henan Cancer Hospital; First Affiliated Hospital Xi'an Jiaotong University; First...

Recruiting

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Sulai Liu

Active, not recruiting

Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Ningbo No. 1 Hospital
Zhejiang University

Recruiting

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Diffuse Large B-cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Colorectal Neoplasms

China
Rutgers, The State University of New Jersey
Natera, Inc.; BioGene Pharmaceutical Ltd.

Recruiting

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Carcinoma, Hepatocellular | Liver Cell Carcinoma

United States
Fudan University

Recruiting

ALPPS Combined With Tislelizumab in Liver Malignancy

Liver Malignant Tumors

China
Zhujiang Hospital

Recruiting

Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

Recurrent Glioblastoma

China
UMC Utrecht

Not yet recruiting

Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal Cancer up to 10 Metastatic Sites (SIRIUS)

Metastatic Colorectal Cancer | Oligometastatic Disease

Netherlands
Daping Hospital and the Research Institute of Surgery...

Recruiting

PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY

Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes

China
Hunan Province Tumor Hospital

Completed

Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC (CLASSIC5)

Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Henan Cancer Hospital

Recruiting

PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

Advanced Melanoma

China
Yanhong Deng

Recruiting

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer (CAMCO2)

Metastatic Colorectal Cancer，NED

China
Lahey Clinic

Completed

Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion

Dry Eye Syndrome

United States
Medical University of Vienna

Recruiting

FMT in IT-refractory HCC - FAB-HCC Pilot Study

Hepatocellular Carcinoma

Austria

3

Subscribe